Guardant Health, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Guardant Health, Inc. on June 12, 2020. The filing reports a corporate governance event: the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
Effective June 12, 2020, the Board of Directors increased its size to seven members and appointed Vijaya Gadde as a Class I director. Ms. Gadde was also appointed to the compensation committee. Her term expires at the 2022 Annual Meeting of Stockholders.
Compensation and Arrangements
- Equity Awards: Ms. Gadde received a stock option award and a restricted stock unit (RSU) award, each valued at $362,500.
- Option Price: The per-share exercise price for the stock option is $77.09.
- Vesting Schedule: One-fourth (1/4) of the awards vest on the first anniversary of her appointment. The remaining three-fourths (3/4) vest monthly over the subsequent three-year period, contingent on continued service.
- Indemnification: The Company entered into a standard indemnification agreement with Ms. Gadde.
Management Commentary and Risks
The filing notes that Ms. Gadde brings significant experience as the Chief Legal Officer of Twitter, Inc., and has served on the boards of NYU Law School and Mercy Corps. There are no reportable transactions or understandings between Ms. Gadde and other persons that would be reportable under Item 404(a) of Regulation S-K.
Investor Verification Checklist
- Verify the total number of directors on the Board is now seven.
- Confirm the vesting schedule details for the $362,500 stock option and RSU awards granted to Ms. Gadde.
- Review the attached press release (Exhibit 99.1) for additional context on the appointment.
- Note that this filing contains no financial results; refer to the most recent 10-Q or 10-K for financial metrics.